Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pontine Glioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively. Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology). - The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Pontine Glioma - Overview Pontine Glioma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Pontine Glioma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Pontine Glioma - Companies Involved in Therapeutics Development AbbVie Inc Arog Pharmaceuticals Inc AstraZeneca Plc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Burzynski Research Institute Inc Insys Therapeutics Inc Loxo Oncology Inc Medicenna Therapeutics Corp Midatech Pharma Plc Novogen Ltd Ono Pharmaceutical Co Ltd Pfizer Inc Sanofi ZIOPHARM Oncology Inc Pontine Glioma - Drug Profiles (A-10 + AS-21) - Drug Profile Product Description Mechanism Of Action R&D Progress AdRTSIL-12 - Drug Profile Product Description Mechanism Of Action R&D Progress afatinib dimaleate - Drug Profile Product Description Mechanism Of Action R&D Progress AZD-1775 - Drug Profile Product Description Mechanism Of Action R&D Progress cabazitaxel - Drug Profile Product Description Mechanism Of Action R&D Progress cannabidiol - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile Product Description Mechanism Of Action R&D Progress crenolanib besylate - Drug Profile Product Description Mechanism Of Action R&D Progress depatuxizumab mafodotin - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress larotrectinib - Drug Profile Product Description Mechanism Of Action R&D Progress MDNA-55 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile Product Description Mechanism Of Action R&D Progress MTX-110 - Drug Profile Product Description Mechanism Of Action R&D Progress MTX-111 - Drug Profile Product Description Mechanism Of Action R&D Progress nivolumab - Drug Profile R&D Progress ORX-101 - Drug Profile Product Description Mechanism Of Action R&D Progress p28 - Drug Profile Product Description Mechanism Of Action R&D Progress pidilizumab - Drug Profile Product Description Mechanism Of Action R&D Progress Trilexium - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Pontine Glioma - Drug Profile Product Description Mechanism Of Action R&D Progress VIMO-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Pontine Glioma - Dormant Projects Pontine Glioma - Product Development Milestones Featured News & Press Releases Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG) Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Pontine Glioma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pontine Glioma - Pipeline by AbbVie Inc, H1 2017 Pontine Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017 Pontine Glioma - Pipeline by AstraZeneca Plc, H1 2017 Pontine Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Pontine Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H1 2017 Pontine Glioma - Pipeline by Insys Therapeutics Inc, H1 2017 Pontine Glioma - Pipeline by Loxo Oncology Inc, H1 2017 Pontine Glioma - Pipeline by Medicenna Therapeutics Corp, H1 2017 Pontine Glioma - Pipeline by Midatech Pharma Plc, H1 2017 Pontine Glioma - Pipeline by Novogen Ltd, H1 2017 Pontine Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Pontine Glioma - Pipeline by Pfizer Inc, H1 2017 Pontine Glioma - Pipeline by Sanofi, H1 2017 Pontine Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017 Pontine Glioma - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
